Free Trial

Celldex Therapeutics Q3 2023 Earnings Report

Celldex Therapeutics logo
$26.04 -0.16 (-0.61%)
(As of 04:28 PM ET)

Celldex Therapeutics EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.67
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Celldex Therapeutics Revenue Results

Actual Revenue
$1.52 million
Expected Revenue
$0.60 million
Beat/Miss
Beat by +$920.00 thousand
YoY Revenue Growth
N/A

Celldex Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A
URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Celldex Therapeutics Earnings Headlines

Celldex announces first patient dosed in Phase 1a study of CDX-622
"X-Ray Vision" could find thousands of hidden market opportunities
Let me show you how I trade with “X-Ray vision.” You see, most “trend” traders only use one trend filter when looking for an optimal buy signal. And that can be a big mistake because you can’t see if you’re in a “True Trend.” But my newest trading tool is designed to only target the best, most stable stocks… Using 3 trend filters… which are these green, yellow, and red lines.
Celldex Therapeutics Reports Q3 2024 Progress and Financials
See More Celldex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email.

About Celldex Therapeutics

Celldex Therapeutics (NASDAQ:CLDX), a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

View Celldex Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings